Literature DB >> 30668431

Anti-inflammation action of xanthones from Swertia chirayita by regulating COX-2/NF-κB/MAPKs/Akt signaling pathways in RAW 264.7 macrophage cells.

Tian-Yong Hu1, Jian-Ming Ju2, Li-Hua Mo1, Li Ma1, Wen-Hui Hu1, Rong-Rong You2, Xue-Qing Chen3, Yan-Yan Chen1, Zhi-Qiang Liu1, Shu-Qi Qiu1, Jun-Ting Fan4, Bao-Hui Cheng5.   

Abstract

BACKGROUND: Swertia chirayita, has been commonly used under the name "Zang-yin-chen" for the treatment of liver infections, inflammation, abdominal pain, and bacterial infection in traditional Tibetan medicine. However, the bioactive components with anti-inflammatory activities and underlying mechanisms remain poorly evaluated. STUDY DESIGN/
METHODS: Repeated column chromatography yielded two main xanthones from petroleum ether (PE) and ethyl acetate fractions of whole plants of S. chirayita, and their structures were determined as bellidifolin (1) and swerchirin (2) on the basis of spectroscopic data and literature analysis. The anti-inflammatory activities and mechanisms of anti-inflammation of these two isolated xanthones were determined via enzyme-linked immunosorbent assay (ELISA) and western blot in lipopolysaccharide (LPS)-stimulated RAW 264.7 murine macrophages in vitro.
RESULTS: Anti-inflammation assay demonstrated that 1 and 2 inhibit the production of the pro-inflammatory cytokines interleukin-6 (IL-6) and TNF-α in LPS-stimulated RAW 264.7 macrophages. Xanthone 1 also potently inhibited the production of prostaglandin E2 (PGE2) by suppressing the protein expression of cyclooxygenase-2 (COX-2) in LPS-stimulated RAW 264.7 macrophages. Western blot showed that the phosphorylation of c-Jun N-terminal kinases (JNK), extracellular signal-regulated kinase (ERK), and p38 MAPKs were remarkably attenuated by 1 in a concentration-dependent manner. Particularly, Compound 1 suppressed the phosphorylation of the inhibitor κB kinase-β (IKK-β), Akt, and p65 subunit of nuclear factor-kappaB (NF-κB).
CONCLUSION: The potent suppressive effects of 1 from S. chirayita on inflammatory mediators by blocking the expression of COX-2 and phosphorylation of Akt, IKK-β, MAPK and NF-κB, activation in LPS-stimulated macrophages suggest that 1 can be a preventive therapeutic candidate for the management of inflammatory-mediated immune disorders.
Copyright © 2018. Published by Elsevier GmbH.

Entities:  

Keywords:  Anti-inflammation; Bellidifolin; COX-2; NF-κB; Swertia chirayita

Mesh:

Substances:

Year:  2018        PMID: 30668431     DOI: 10.1016/j.phymed.2018.08.001

Source DB:  PubMed          Journal:  Phytomedicine        ISSN: 0944-7113            Impact factor:   5.340


  14 in total

Review 1.  Phosphoinositide 3-kinase/Akt and its related signaling pathways in the regulation of tumor-associated macrophages polarization.

Authors:  Depeng Yang; Lijun Yang; Jialing Cai; Huaxin Li; Zheng Xing; Ying Hou
Journal:  Mol Cell Biochem       Date:  2022-05-19       Impact factor: 3.842

2.  Scutellarein Inhibits LPS-Induced Inflammation through NF-κB/MAPKs Signaling Pathway in RAW264.7 Cells.

Authors:  Min Yeong Park; Sang Eun Ha; Hun Hwan Kim; Pritam Bhagwan Bhosale; Abuyaseer Abusaliya; Se Hyo Jeong; Joon-Suk Park; Jeong Doo Heo; Gon Sup Kim
Journal:  Molecules       Date:  2022-06-12       Impact factor: 4.927

3.  Cerevisterol Alleviates Inflammation via Suppression of MAPK/NF-κB/AP-1 and Activation of the Nrf2/HO-1 Signaling Cascade.

Authors:  Md Badrul Alam; Nargis Sultana Chowdhury; Md Hossain Sohrab; Md Sohel Rana; Choudhury Mahmood Hasan; Sang-Han Lee
Journal:  Biomolecules       Date:  2020-01-29

4.  Combined Lycium babarum polysaccharides and C-phycocyanin increase gastric Bifidobacterium relative abundance and protect against gastric ulcer caused by aspirin in rats.

Authors:  Shu-Yu Hsieh; Yu Zhi Lian; I-Hsuan Lin; Yu-Chen Yang; Alexey A Tinkov; Anatoly V Skalny; Jane C-J Chao
Journal:  Nutr Metab (Lond)       Date:  2021-01-06       Impact factor: 4.169

Review 5.  Bellidifolin Inhibits Proliferation of A549 Cells by Regulating STAT3/COX-2 Expression and Protein Activity.

Authors:  Li Yan; Luo Yali; Li Chenghao; Feng Caiqin; Zhu Zhongbo; Ren Weiyu; Ma Yu; Zhou Xiaotian; Wang Biwen; Jin Xiaojie; Liu Yongqi
Journal:  J Oncol       Date:  2020-11-21       Impact factor: 4.375

6.  AYUSH-64 as an add-on to standard care in asymptomatic and mild cases of COVID-19: A randomized controlled trial.

Authors:  R Govind Reddy; Rajesh Vithal Gosavi; Babita Yadav; Amit Kumar Rai; Madhuri Prashant Holay; Manisha Talekar; Sophia Jameela; Bhagwan Sahay Sharma; Shruti Khanduri; Rakesh Rana; Arunabh Tripathi; Bhogavalli Chandrasekhararao; Narayanam Srikanth; Kartar S Dhiman
Journal:  Ayu       Date:  2021-10-23

7.  Role of the miR-133a-5p/FBXO6 axis in the regulation of intervertebral disc degeneration.

Authors:  Xian-Fa Du; Hai-Tao Cui; He-Hai Pan; Jun Long; Hao-Wen Cui; Shun-Lun Chen; Jian-Ru Wang; Ze-Min Li; Hui Liu; Yong-Can Huang; Hua Wang; Zhao-Min Zheng
Journal:  J Orthop Translat       Date:  2021-06-19       Impact factor: 5.191

8.  Chlojaponilactone B Attenuates Lipopolysaccharide-Induced Inflammatory Responses by Suppressing TLR4-Mediated ROS Generation and NF-κB Signaling Pathway.

Authors:  Shaoxia Ye; Qiyao Zheng; Yang Zhou; Bai Bai; Depo Yang; Zhimin Zhao
Journal:  Molecules       Date:  2019-10-16       Impact factor: 4.411

9.  Activation of Nrf2/HO-1 by Peptide YD1 Attenuates Inflammatory Symptoms through Suppression of TLR4/MYyD88/NF-κB Signaling Cascade.

Authors:  Md Saifur Rahman; Md Badrul Alam; Young Kyun Kim; Mst Hur Madina; Ismail Fliss; Sang Han Lee; Jin Cheol Yoo
Journal:  Int J Mol Sci       Date:  2021-05-13       Impact factor: 5.923

10.  Randomized double blind clinical trial evaluating the Ellagic acid effects on insulin resistance, oxidative stress and sex hormones levels in women with polycystic ovarian syndrome.

Authors:  Maria Kavianpour; Hossein Khadem Haghighian; Mahnaz Kazemi; Fatemeh Lalooha; Mohammadreza Rashidi Nooshabadi; Fariba Dashti
Journal:  J Ovarian Res       Date:  2021-07-31       Impact factor: 4.234

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.